Previous Article | Next Article 
Journal of Clinical Microbiology, March 2006, p. 1105-1107, Vol. 44, No. 3
0095-1137/06/$08.00+0 doi:10.1128/JCM.44.3.1105-1107.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Respiratory Syncytial Virus Detection by Remel Xpect, Binax Now RSV, Direct Immunofluorescent Staining, and Tissue Culture
Anita P. Borek,
Susan H. Clemens,
Valerie K. Gaskins,
Deborah Z. Aird, and
Alexandra Valsamakis*
Johns Hopkins Medical Institutions, 600 North Wolfe Street, Meyer Building, Room B1-193, Baltimore, Maryland 21287-7093
Received 7 November 2005/
Returned for modification 21 December 2005/
Accepted 27 December 2005

ABSTRACT
The performance characteristics of Xpect RSV (XP) and Binax
Now RSV (BN) were compared to those of direct fluorescent-antibody
staining and/or tissue culture for detection of respiratory
syncytial virus (RSV) in nasopharyngeal aspirate and wash samples
from children (
n = 110) and adults (
n = 66). The sensitivity,
specificity, positive predictive value, and negative predictive
value of XP were 75%, 98%, 95%, and 90%, respectively; and those
of BN were 74%, 100%, 100%, and 90%, respectively. The performances
of the assays were similar within a given age group and specimen
type (nasopharyngeal aspirate or wash specimen). XP and BN are
useful for screening for RSV in respiratory specimens when large
volumes are tested or low levels of staffing occur.

TEXT
Respiratory syncytial virus (RSV) is a negative-strand RNA virus
and is a member of the pneumovirus subfamily of the family
Paramyxoviridae.
It is known as a major cause of respiratory tract illness in
children, and it is increasingly recognized as a significant
respiratory pathogen in adults (
3). Nosocomial outbreaks are
well recognized (
2,
4). Effective approaches to decreasing the
rates of nosocomial transmission rely on rapid laboratory diagnosis
(
5,
6). Rapid direct RSV detection methods vary in their complexities.
Lateral flow, membrane-based immunochromatographic assays have
certain advantages compared to direct fluorescent-antibody staining
(DFA), including an ultrarapid turnaround time and low levels
of complexity. The goal of this study was to determine the performance
characteristics of two immunochromatographic methods (Xpect
RSV [XP] and Binax Now RSV [BN]) to those of a combined standard
of DFA and/or culture (shell vial and conventional tube assays)
with nasopharyngeal swab specimens collected in an urban tertiary-care
setting.
Nasopharyngeal samples (n = 176 total samples; nasopharyngeal aspirates [NPAs], n = 130; nasopharyngeal washes [NPW], n = 46) were collected from children (n = 110; age range, 6 months to 18 years) and adults (n = 66) for routine medical care. Specimens were received in M4RT viral transport medium (approximate volume, 3 ml; Remel Inc., Lenexa, KS). Specimens were not further diluted prior to testing. Each specimen was tested by XP, BN, DFA (IMAGEN, Dakocytomation, Carpinteria, CA), and culture, according to the manufacturers' instructions. Uncentrifuged specimens were used for testing by XP and BN. NPAs have been approved for use with XP but not BN. Both tests have been approved for use with NPWs. After migration control failure in the XP device, samples were extracted and retested according to the instructions in the package insert. For extractions, 2 drops of proprietary extraction buffer were added to 250 µl of specimen. Following mixing of the contents, XP was repeated by applying 3 to 4 drops of extracted specimen to an XP device. For DFA, specimens were considered adequate if three or more cells were present per x200 field. Cell culture was performed with R-Mix shell vials (Diagnostic Hybrids, Inc. [DHI], Athens, OH) and tubes containing rhesus monkey cells (DHI). Shell vials were incubated for 2 days and were then stained with fluorescein isothiocyanate (FITC)-conjugated monoclonal antibody (DHI), according to the instructions in the package insert. The tubes were examined daily for 10 days and then biweekly for an additional 11 days. RSV growth was confirmed by staining washed cell pellets with FITC-conjugated monoclonal antibody (DHI).
Data were compiled in Excel software (Microsoft Corp., Redmond, WA). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the immunochromatographic methods were calculated in comparison to a combined standard of DFA and culture results. A sample with a true-positive result was defined as any sample that was positive by DFA and/or culture (DFA positive and culture positive, n = 38; DFA positive and culture negative, n = 5; DFA negative and culture positive, n = 5; DFA uninterpretable and culture positive, n = 1). A sample with a true-negative result was defined as any sample that was negative by DFA and culture (n = 115). XP data were calculated on the basis of the extraction results when the initial results were uninterpretable. Specimens that were uninterpretable by DFA and negative by culture were excluded from the final data set (n = 12) since a definitive result for RSV could not be obtained. Additionally, specimens that were uninterpretable by XP or BN (Table 1) were not used for calculation of the sensitivity, specificity, PPV, and NPV. No specimens were found to be positive by both immunochromatographic tests but negative or uninterpretable by the combined standard. This study was approved by The Johns Hopkins Medicine Institutional Review Board.
View this table:
[in this window]
[in a new window]
|
TABLE 1. Comparative results between immunochromatographic methods and combined standard (DFA and/or culture) for RSV
|
The results obtained with XP and BN compared to those obtained
by DFA and/or culture are shown in Table
1. Based on these data,
the sensitivity, specificity, PPV, and NPV of XP were 75%, 98%,
95%, and 90%, respectively; and those of BN were 74%, 100%,
100%, and 90%, respectively (Table
2). The prevalence of RSV
in the total population was 27%. The performance characteristics
within a single age group were almost entirely equivalent between
the two immunochromatographic tests (Table
2). In a comparison
between specimen types (i.e., NPWs versus NPAs for XP and NPWs
versus NPAs for BN), the sensitivity, specificity, and PPV were
equivalent for each individual immunochromatographic assay (Table
2). In addition, the sensitivity, specificity, and PPV were
equivalent for each individual sample type when the results
of XP and BN were compared (i.e., NPAs by XP and BN and NPWs
by XP and BN) (Table
2). The NPVs were lower for both assays
when NPAs were used compared to the NPVs obtained when NPWs
were used (Tables
1 and
2).
View this table:
[in this window]
[in a new window]
|
TABLE 2. Clinical performance characteristics of rapid detection tests compared to those of the combined standard
|
Analysis of specimens with uninterpretable results demonstrated
internal control failure rates of 28% (49 of 176 samples) and
1% (2 of 176 samples) (Table
1) for XP and BN, respectively.
After extraction and repeat testing, 3% (six samples) remained
uninterpretable by XP (Table
1). For DFA, 7% of specimens contained
an insufficient number of cells and were therefore uninterpretable
(
n = 13 specimens in total; DFA uninterpretable and culture
negative,
n = 12; DFA uninterpretable and culture positive,
n = 1).
This study demonstrated that the performance characteristics of XP and BN were comparable for the total study population and within stratified age groups. There are no previously published reports on the performance of XP. For BN, the high specificity (1, 7), positive predictive value (7), and negative predictive value (7, 8) with samples from children were consistent with previously published data. In this study the sensitivity of BN was lower than that previously reported with samples from children (1, 7, 8). In contrast, with samples from adults, we observed a greater number of positive results than was previously described for BN (4 positive results of 66 tested). In the only other study describing the performance of BN with samples from adults, BN failed to detect RSV in any adult specimens (n = 34) (7).
One potential explanation for the decreased sensitivities of BN and XP that we observed is diminished performance with NPAs, the predominant specimen in the study set. No other comparative data on immunochromatography test performance with NPAs are available. Previously published studies of BN used a combination of nasal or nasopharyngeal aspirates and washes; however, the data were not stratified by specimen type. Of note, we observed that the sensitivity of BN with NPWs (75%) was lower than that reported in the package insert (89%). Therefore, whether our data reflect diminished assay sensitivity with NPAs or variable performance in different clinical settings is unclear.
One advantage of BN compared to XP and DFA was the low rate of uninterpretable results after initial testing. For XP, internal control failure was observed in approximately one-third of specimens. This high rate of uninterpretable results resolved after extraction; however, the additional extraction steps decreased the ease of use and the time to retrieval of the results.
Immunochromatographic tests such as XP and BN are ideal during the respiratory virus season, when rapid, simple tests can help virology laboratories effectively handle large increases in testing volumes. Additionally, these low-complexity tests are extremely useful during off shifts, when staffing is low. However, our data suggest that these ultrarapid methods are best performed as screening tests, given their relative insensitivities compared to the sensitivities DFA and culture. Laboratories should continue to perform additional, sensitive diagnostic tests with specimens that test negative.

ACKNOWLEDGMENTS
We thank the staff of The Johns Hopkins Clinical Virology Laboratory
for technical support and Remel for providing reagents. We also
thank William Merz and Michael Forman for comments and suggestions
on this work.

FOOTNOTES
* Corresponding author. Mailing address: Johns Hopkins Medical Institutions, Meyer Building, Room B1-193, 600 N. Wolfe St., Baltimore, MD 21287-7093. Phone: (410) 955-5077. Fax: (410) 614-8087. E-mail:
avalsam1{at}jhmi.edu.


REFERENCES
1 - Aldous, W. K., K. Gerber, E. W. Taggart, J. Thomas, D. Tidwell, and J. A. Daly. 2004. A comparison of Binax NOW to viral culture and direct fluorescent assay testing for respiratory syncytial virus. Diagn. Microbiol. Infect. Dis. 49:265-268.[CrossRef][Medline]
2 - Berner, R., F. Schwoerer, R. F. Schumacher, M. Meder, and J. Forster. 2001. Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999. Eur. J. Pediatr. 160:541-547.[CrossRef][Medline]
3 - Falsey, A. R., P. A. Hennessey, M. A. Formica, C. Cox, and E. E. Walsh. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352:1749-1759.[Abstract/Free Full Text]
4 - Forster, J., G. Ihorst, C. H. Rieger, V. Stephan, H. D. Frank, H. Gurth, R. Berner, A. Rohwedder, H. Werchau, M. Schumacher, T. Tsai, and G. Petersen. 2004. Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRI. DE study). Eur. J. Pediatr. 163:709-716.[CrossRef][Medline]
5 - Leclair, J. M., J. Freeman, B. F. Sullivan, C. M. Crowley, and D. A. Goldmann. 1987. Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N. Engl. J. Med. 317:329-334.[Abstract]
6 - Madge, P., J. Y. Paton, J. H. McColl, and P. L. Mackie. 1992. Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus. Lancet 340:1079-1083.[CrossRef][Medline]
7 - Ohm-Smith, M. J., P. S. Nassos, and B. L. Haller. 2004. Evaluation of the Binax NOW, BD Directigen, and BD Directigen EZ assays for detection of respiratory syncytial virus. J. Clin. Microbiol. 42:2996-2999.[Abstract/Free Full Text]
8 - Zheng, X., S. Quianzon, Y. Mu, and B. Z. Katz. 2004. Comparison of two new rapid antigen detection assays for respiratory syncytial virus with another assay and shell vial culture. J. Clin. Virol. 31:130-133.[CrossRef][Medline]
Journal of Clinical Microbiology, March 2006, p. 1105-1107, Vol. 44, No. 3
0095-1137/06/$08.00+0 doi:10.1128/JCM.44.3.1105-1107.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Liao, R. S., Tomalty, L. L., Majury, A., Zoutman, D. E.
(2009). Comparison of Viral Isolation and Multiplex Real-Time Reverse Transcription-PCR for Confirmation of Respiratory Syncytial Virus and Influenza Virus Detection by Antigen Immunoassays. J. Clin. Microbiol.
47: 527-532
[Abstract]
[Full Text]
-
Mahony, J. B.
(2008). Detection of Respiratory Viruses by Molecular Methods. Clin. Microbiol. Rev.
21: 716-747
[Abstract]
[Full Text]
-
Cruz, A. T., Cazacu, A. C., Greer, J. M., Demmler, G. J.
(2007). Performance of a Rapid Assay (Binax NOW) for Detection of Respiratory Syncytial Virus at a Children's Hospital over a 3-Year Period. J. Clin. Microbiol.
45: 1993-1995
[Abstract]
[Full Text]
-
Leland, D. S., Ginocchio, C. C.
(2007). Role of Cell Culture for Virus Detection in the Age of Technology. Clin. Microbiol. Rev.
20: 49-78
[Abstract]
[Full Text]